Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajanikanth Madabushi

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pharmacology|September 30, 2011
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairmentSudharshan Hariharan, Rajanikanth Madabushi
CPT: Pharmacometrics & Systems Pharmacology|December 25, 2018
A Holistic and Integrative Approach for Advancing Model-Informed Drug DevelopmentRajanikanth Madabushi, Yaning Wang, Issam Zineh
Journal of Clinical Pharmacology|July 22, 2014
Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it meansSudharshan Hariharan, Mary Ross Southworth, Rajanikanth Madabushi
Clinical and Translational Science|February 12, 2019
Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology EvaluationNina Isoherranen, Rajanikanth Madabushi, Shiew-Mei Huang
Chest|June 28, 2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthmaKathryn Blake, Rajanikanth Madabushi, Hartmut Derendorf, et al.
Journal of Clinical Pharmacology|October 4, 2024
Addressing Drug-Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023Sarah Ridge, Xinning Yang, Rajanikanth Madabushi, et al.
Clinical Pharmacology and Therapeutics|March 6, 2024
The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to PathwayRajanikanth Madabushi, Jessica Benjamin, Hao Zhu, et al.
Clinical Pharmacology and Therapeutics|June 20, 2022
Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter-Mediated Drug InteractionsXinning Yang, Kellie Reynolds, Rajanikanth Madabushi, et al.
European Journal of Clinical Pharmacology|February 16, 2006
Hyperforin in St. John's wort drug interactionsRajanikanth Madabushi, Bruno Frank, Bernd Drewelow, et al.
Journal of the American Geriatrics Society|April 3, 2024
Closing the gap: A United States perspective on enhancing drug evaluation in older adultsS W Johnny Lau, Qi Liu, Rajanikanth Madabushi, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|September 30, 2011
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairmentSudharshan Hariharan, Rajanikanth Madabushi
CPT: Pharmacometrics & Systems Pharmacology|December 25, 2018
A Holistic and Integrative Approach for Advancing Model-Informed Drug DevelopmentRajanikanth Madabushi, Yaning Wang, Issam Zineh
Journal of Clinical Pharmacology|July 22, 2014
Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it meansSudharshan Hariharan, Mary Ross Southworth, Rajanikanth Madabushi
Clinical and Translational Science|February 12, 2019
Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology EvaluationNina Isoherranen, Rajanikanth Madabushi, Shiew-Mei Huang
Chest|June 28, 2008
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthmaKathryn Blake, Rajanikanth Madabushi, Hartmut Derendorf, et al.
Journal of Clinical Pharmacology|October 4, 2024
Addressing Drug-Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023Sarah Ridge, Xinning Yang, Rajanikanth Madabushi, et al.
Clinical Pharmacology and Therapeutics|March 6, 2024
The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to PathwayRajanikanth Madabushi, Jessica Benjamin, Hao Zhu, et al.
Clinical Pharmacology and Therapeutics|June 20, 2022
Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter-Mediated Drug InteractionsXinning Yang, Kellie Reynolds, Rajanikanth Madabushi, et al.
European Journal of Clinical Pharmacology|February 16, 2006
Hyperforin in St. John's wort drug interactionsRajanikanth Madabushi, Bruno Frank, Bernd Drewelow, et al.
Journal of the American Geriatrics Society|April 3, 2024
Closing the gap: A United States perspective on enhancing drug evaluation in older adultsS W Johnny Lau, Qi Liu, Rajanikanth Madabushi, et al.
Pageof 7